文献速递神经肿瘤

重新审视成人型弥漫性胶质瘤中大脑胶质瘤病的预后因素

Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas.
PubMed 文献 · J Neurooncol · 2024-05-03

该回顾性研究纳入2005至2021年单中心99例成人型弥漫性胶质瘤相关大脑胶质瘤病(GC)患者,分析临床、分子、影像及手术因素对总生存的影响。全组中位OS为16.7个月,IDH野生型胶质母细胞瘤患者为14.3个月;多因素分析显示KPS、1p/19q共缺失、MGMT启动子甲基化及出血是全组独立预后因素。作者结论认为GC预后取决于分子类型与体能状态,且对强化肿瘤行积极手术未改善生存。

要点

  • 全组中位OS为16.7个月,IDH野生型胶质母细胞瘤患者为14.3个月。
  • 全组独立预后因素:KPS(HR=0.98,P=0.004)、无1p/19q共缺失(HR=10.75,P=0.019)、MGMT启动子甲基化(HR=0.54,P=0.028)、出血(HR=3.45,P=0.001)。
  • IDH野生型胶质母细胞瘤中仅KPS为独立预后因素(HR=2.24,P=0.075);强化肿瘤全切除未达显著预后意义(HR=1.13,P=0.685)。

核心结论

  • GC患者的预后由其潜在的分子类型和患者体能状态决定。
  • 与无GC的弥漫性胶质瘤相比,对GC患者强化肿瘤行积极手术并未改善生存。

研究设计与样本

  • 回顾性病历与影像复习,纳入2005年至2021年单中心1211例成人型弥漫性胶质瘤中的99例GC患者(6例少突胶质细胞瘤、16例IDH突变型星形细胞瘤、77例IDH野生型胶质母细胞瘤)。
  • 分析全组患者及IDH野生型胶质母细胞瘤患者的总生存预测因素。

主要发现

  • 全组中位OS为16.7个月(95%CI 14.2-22.2),IDH野生型胶质母细胞瘤患者中位OS为14.3个月(95%CI 12.2-61.9)。
  • 全组多因素分析显示KPS(HR=0.98,P=0.004)、无1p/19q共缺失(HR=10.75,P=0.019)、MGMT启动子甲基化(HR=0.54,P=0.028)及出血(HR=3.45,P=0.001)为独立预后因素。
  • IDH野生型胶质母细胞瘤患者多因素分析中,KPS(HR=2.24,P=0.075)是唯一独立预后因素。
  • 在IDH野生型胶质母细胞瘤伴强化肿瘤的亚组中,强化肿瘤全切除未保持为显著预后因素(HR=1.13,P=0.685)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is lack of comprehensive analysis evaluating the impact of clinical, molecular, imaging, and surgical data on survival of patients with gliomatosis cerebri (GC). This study aimed to investigate prognostic factors of GC in adult-type diffuse glioma patients. METHODS: Retrospective chart and imaging review was performed in 99 GC patients from adult-type diffuse glioma (among 1,211 patients; 6 oligodendroglioma, 16 IDH-mutant astrocytoma, and 77 IDH-wildtype glioblastoma) from a single institution between 2005 and 2021. Predictors of overall survival (OS) of entire patients and IDH-wildtype glioblastoma patients were determined. RESULTS: The median OS was 16.7 months (95% confidence interval [CI] 14.2-22.2) in entire patients and 14.3 months (95% CI 12.2-61.9) in IDH-wildtype glioblastoma patients. In entire patients, KPS (hazard ratio [HR] = 0.98, P = 0.004), no 1p/19q codeletion (HR = 10.75, P = 0.019), MGMTp methylation (HR = 0.54, P = 0.028), and hemorrhage (HR = 3.45, P = 0.001) were independent prognostic factors on multivariable analysis. In IDH-wildtype glioblastoma patients, KPS (HR = 2.24, P = 0.075) was the only independent prognostic factor on multivariable analysis. In subgroup of IDH-wildtype glioblastoma with CE tumors, total resection of CE tumor did not remain as a significant prognostic factor (HR = 1.13, P = 0.685). CONCLUSIONS: The prognosis of GC patients is determined by its underlying molecular type and patient performance status. Compared with diffuse glioma without GC, aggressive surgery of CE tumor in GC patients does not improve survival.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Shin I, Sim Y, Choi SH, et al. Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas. J Neurooncol. 2024. PMID: 38700610. doi:10.1007/s11060-024-04656-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。